GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

RNST · Jun 30, 2024

RENASANT CORP. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0000715072-24-000155Bank
Sequential deposit growth25thOwn-history percentile · N=20
Evidence method

Sequential · gp.financial.deposits

0.13% · CORE · VALID

Net-income growth80thOwn-history percentile · N=20
Evidence method

Yoy · gp.fundamentals.net_income

35.62% · CORE · VALID

Interest-income growth50thOwn-history percentile · N=20
Evidence method

Yoy · gp.financial.interest_income

11.69% · CORE · VALID

Cash and equivalents65thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.cash

$851.9M · CORE · VALID

Sequential loan growth24thOwn-history percentile · N=17
Evidence method

Sequential · gp.financial.loans

0.86% · CORE · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History37 statesSelf-history eligible
Period transition

What moved in the state?

Deposit Growth Decreased
Previous
1.14%
Current
0.13%
Delta
-1.01%
Earnings Growth Increased
Previous
-14.47%
Current
35.62%
Delta
50.09%
Interest Income Growth Decreased
Previous
15.83%
Current
11.69%
Delta
-4.14%
Liquidity Increased
Previous
$844.4M
Current
$851.9M
Delta
$7.5M
Loan Growth Decreased
Previous
1.21%
Current
0.86%
Delta
-0.35%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.